New hope for Tough-to-Treat breast cancer: testing a Triple-Drug attack
NCT ID NCT07333937
Summary
This study is testing a new combination of three drugs (neratinib, fulvestrant, and eribulin) for people with a specific type of advanced breast cancer. It is for patients whose cancer has continued to grow despite treatment with a common drug called trastuzumab deruxtecan. The goal is to see if this three-drug approach can help control the cancer and is safe for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.